Investigating the Effects of Systemically Administered Strontium Ranelate on Alveolar Bone Loss Histomorphometrically...

Area of Science:

• Periodontology
• Pharmacology
• Bone Biology

Background:

• Experimental periodontitis is characterized by alveolar bone loss (ABL).
• Strontium ranelate (SR) is investigated for its potential therapeutic effects on bone metabolism.
• Understanding SR's impact on periodontitis is crucial for developing new treatments.

Purpose of the Study:

• To evaluate the efficacy of strontium ranelate (SR) in mitigating alveolar bone loss (ABL) in a rat model of experimental periodontitis.
• To assess the effects of varying SR dosages on key cellular and molecular markers associated with periodontal disease progression.

Main Methods:

• A rat model of experimental periodontitis was established using silk ligatures around molars.
• Rats were treated with different doses of strontium ranelate (SR) or served as controls.
• Alveolar bone loss (ABL), osteoclast and osteoblast numbers, and serum levels of IL-1β, OPG, and BALP were analyzed. Receptor activator of nuclear factor-kappa B ligand (RANKL) activity was also assessed.

Main Results:

• Strontium ranelate (SR) administration, particularly at the highest dose (SR900), significantly reduced alveolar bone loss (ABL) compared to the ligated control group.
• Osteoclast numbers were significantly decreased in SR-treated groups, while osteoblast numbers were increased, indicating modulation of bone remodeling.
• RANKL activity was reduced in the SR900 group, suggesting a mechanism for SR's bone-protective effects.

Conclusions:

• Strontium ranelate (SR) demonstrates a therapeutic potential in reducing alveolar bone loss (ABL) associated with experimental periodontitis.
• SR effectively modulates bone remodeling by decreasing osteoclast activity and potentially increasing osteoblast activity.
• The findings suggest SR could be a viable therapeutic agent for managing periodontal bone destruction.